title: RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes             multidrug-resistant hepatocellular carcinoma cells to chemotherapy.
abstract: The histone-lysine N-methyltransferase, enhancer of zeste homologue 2 (EZH2),             functions as a transcriptional repressor and plays an important role in the development             of various types of cancer. In this study, we observed the increased EZH2 expression             in the Bel/FU multidrug-resistant hepatocellular carcinoma (HCC) cell line. The             RNA interference (RNAi)-mediated depletion of EZH2 expression in the Bel/FU cells             led to decreased multidrug resistance protein 1 (MDR1) expression, which resulted             in increased apoptosis and sustained G1/S phase arrest. Moreover, siRNA targeting             EZH2 sensitized Bel/FU cells to 5-fluorouracil treatment. These findings suggest             that EZH2 plays a role in the development of multidrug resistance and may represent             a novel therapeutic target for multidrug-resistant HCC.
authors.affiliation: Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, PR China.
authors.forename: Bo
authors.initials: B
authors.lastname: Tang
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Rui
authors.initials: R
authors.lastname: Liang
authors.forename: Zhenming
authors.initials: Z
authors.lastname: Gao
authors.forename: Deguang
authors.initials: D
authors.lastname: Sun
authors.forename: Liming
authors.initials: L
authors.lastname: Wang
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism*; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis; D006528:Carcinoma, Hepatocellular; D045744:Cell Line, Tumor; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D000071221:Enhancer of Zeste Homolog 2 Protein; D005472:Fluorouracil / Q000494:pharmacology*; D059585:G1 Phase Cell Cycle Checkpoints; D055785:Gene Knockdown Techniques; D006801:Humans; D008113:Liver Neoplasms; D063151:Polycomb Repressive Complex 2 / Q000235:genetics* / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000964:Antimetabolites, Antineoplastic; D034741:RNA, Small Interfering; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; D005472:Fluorouracil